Aldo-Keto Reductases: Multifunctional Proteins as Therapeutic Targets in Diabetes and Inflammatory Disease

Area of Science:

• Biochemistry
• Molecular Biology
• Ophthalmology

Background:

• Aldose reductase (AR) is implicated in blinding diseases including uveitis, diabetic retinopathy (DR), and cataract.
• The precise mechanisms linking AR activity to these pathologies remain unclear.
• AR's role extends to cancer development and progression, as indicated by inhibitor studies and gene-targeted mice.

Purpose of the Study:

• To review the molecular signaling pathways associated with aldose reductase.
• To elucidate the mechanisms by which AR inhibition could be a therapeutic strategy for eye diseases and cancer.

Main Methods:

• Literature review of studies on aldose reductase inhibitors.
• Analysis of research involving gene-targeted mice models.
• Examination of molecular signaling cascades linked to AR.

Main Results:

• AR plays a role in the pathogenesis of uveitis, diabetic retinopathy, and cataract.
• AR inhibition demonstrates potential efficacy in preclinical models of these eye conditions.
• Evidence suggests AR's involvement in the molecular mechanisms of colon cancer onset and progression.

Conclusions:

• Aldose reductase is a key enzyme in the development of several blinding eye diseases.
• Inhibiting aldose reductase presents a promising therapeutic avenue for diabetic retinopathy, cataract, and uveitis.
• Understanding AR's role in molecular signaling provides a basis for its potential as an anti-cancer target.